The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients
Open accessAbstract
BACKGROUND: To evaluate the safety of thiopurines in patients with inflammatory bowel disease. To identify predictive factors associated with the development of thiopurine-induced adverse events. METHODS: Long-term incidence of adverse events was estimated in patients from a prospectively maintained Spanish nationwide database using Kaplan-Meier analysis. Cox regression analysis was performed to identify potential predictive factors of adverse events. RESULTS: Three thousand nine hundred and thirty-one patients were included. Ninety-five percent of patients were on azathioprine. The median follow-up with thiopurines was 44 months (range, 0-420). Adverse events occurred at a median of 1 month after starting treatment. The cumulative incidence of adverse events was 26%, with an annual risk of 7% per patient-year of treatment. Most frequent adverse events were nausea (8%), hepatotoxicity (4%), myelotoxicity (4%), and pancreatitis (4%). Four patients had lymphoma. Female and Crohn's disease increased the risk of having nausea. The risk of hepatotoxicity was lower in females and higher in Crohn's disease. The risk of myelotoxicity was significantly higher in patients treated with mercaptopurine and in females. The risk of pancreatitis was higher in Crohn's disease. Overall, 17% of patients discontinued thiopurine treatment due to adverse events. Thirty-seven percent of these patients started thiopurines again and 40% of them had adverse events again. CONCLUSIONS: As many as 1 of 4 patients on thiopurine therapy had adverse events during follow-up. A relatively high proportion of patients (17%) had to discontinue the treatment with thiopurines due to adverse events. However, more than half of patients that restarted thiopurine treatment after its discontinuation due to adverse events tolerated it. Several predictive factors for some adverse events have been identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beaugerie, L., Brousse, N., Bouvier, A. M., Colombel, J. F., Lémann, M., Cosnes, J., Hébuterne, X., Cortot, A., Bouhnik, Y., Gendre, J. P., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61302-7 · Cited by 1,115
Kandiel, A., Fraser, A. G., Korelitz, B. I., Brensinger, C., & Lewis, J. D. (2005) · Gut · doi:10.1136/gut.2004.049460 · Cited by 808
The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review
Fraser, A. G. (2002) · Gut · doi:10.1136/gut.50.4.485 · Cited by 629
Colombel, J., Ferrari, N., Debuysere, H., Marteau, P., Gendre, J., Bonaz, B., Soulé, J.-C., Modigliani, R., Touze, Y., Catala, P., et al. (2000) · Gastroenterology · doi:10.1016/s0016-5085(00)70354-4 · Cited by 619
European evidence-based Consensus on the management of ulcerative colitis: Current management
Travis, S. P. L., Stange, E. F., Lémann, M., Øresland, T., Bemelman, W. A., Chowers, Y., Colombel, J. F., D'Haens, G., Ghosh, S., Marteau, P., et al. (2008) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2007.11.002 · Cited by 558
Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience.
Connell, W. R., Kamm, M. A., Ritchie, J. K., & Lennard-Jones, J. E. (1993) · Gut · doi:10.1136/gut.34.8.1081 · Cited by 510
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
Bouhnik, Y., Scemama, G., Taï, R., Matuchansky, C., Rambaud, J.-C., Lémann, M., Modigliani, R., & Mary, J.-Y. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90402-x · Cited by 466
Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease
Chande, N., Patton, P. H., Tsoulis, D. J., Thomas, B. S., & MacDonald, J. K. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000067.pub3 · Cited by 402
Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review
Gisbert, J. P., & Gomolln, F. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01848.x · Cited by 253
Self-citationMeta‐analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis
GISBERT, J. P., LINARES, P. M., MCNICHOLL, A. G., MATÉ, J., & GOMOLLÓN, F. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04023.x · Cited by 218
Self-citation
Cited by
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Shelton, J., Lu, X., Hollenbaugh, J. A., Cho, J. H., Amblard, F., & Schinazi, R. F. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00209 · Cited by 409
Gastrointestinal Tract Disorders in Older Age
Dumic, I., Nordin, T., Jecmenica, M., Stojkovic Lalosevic, M., Milosavljevic, T., & Milovanovic, T. (2019) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2019/6757524 · Cited by 314
Systematic review with meta-analysis: inflammatory bowel disease in the elderly
Gisbert, J. P., & Chaparro, M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12616 · Cited by 158
Self-citation
Metadata
- Authors
- Chaparro, M., Ordás, I., Cabré, E., Garcia-Sanchez, V., Bastida, G., Peñalva, M., Gomollón, F., García-Planella, E., Merino, O., Gutiérrez, A., Esteve, M., Márquez, L., Garcia-Sepulcre, M., Hinojosa, J., Vera, I., Muñoz, F., Mendoza, J. L., Cabriada, J. L., Montoro, M. A., Barreiro-de Acosta, M., Ceña, G., Saro, C., Aldeguer, X., Barrio, J., Maté, J., & Gisbert, J. P.
- Venue
- Inflammatory Bowel Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-06
- Volume
- 19
- Issue
- 7
- Pages
- 1404-1410
- ISSN
- 1078-0998 (ISSN-L)
- OpenAlex
- W2035746880
- Cited by
- 297
- References
- 26
- FWCI
- 14.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients. https://app.cochat.ai/papers/10.1097/mib.0b013e318281f28f
- The paper
- Chaparro, M., Ordás, I., Cabré, E., Garcia-Sanchez, V., Bastida, G., Peñalva, M., Gomollón, F., García-Planella, E., Merino, O., Gutiérrez, A., Esteve, M., Márquez, L., Garcia-Sepulcre, M., Hinojosa, J., Vera, I., Muñoz, F., Mendoza, J. L., Cabriada, J. L., Montoro, M. A., . . . Gisbert, J. P. (2013). Safety of Thiopurine Therapy in Inflammatory Bowel Disease: Long-term Follow-up Study of 3931 Patients. Inflammatory Bowel Diseases. https://doi.org/10.1097/mib.0b013e318281f28f
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.